MX2020002769A - Composiciones de polvo seco con estearato de magnesio. - Google Patents

Composiciones de polvo seco con estearato de magnesio.

Info

Publication number
MX2020002769A
MX2020002769A MX2020002769A MX2020002769A MX2020002769A MX 2020002769 A MX2020002769 A MX 2020002769A MX 2020002769 A MX2020002769 A MX 2020002769A MX 2020002769 A MX2020002769 A MX 2020002769A MX 2020002769 A MX2020002769 A MX 2020002769A
Authority
MX
Mexico
Prior art keywords
dry powder
compositions
magnesium stearate
âμm
powder composition
Prior art date
Application number
MX2020002769A
Other languages
English (en)
Spanish (es)
Inventor
Kambiz Yadidi
Original Assignee
Otitopic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otitopic Inc filed Critical Otitopic Inc
Publication of MX2020002769A publication Critical patent/MX2020002769A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0023—Mouthpieces therefor retractable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2020002769A 2017-09-22 2017-09-26 Composiciones de polvo seco con estearato de magnesio. MX2020002769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762562295P 2017-09-22 2017-09-22
PCT/US2017/053569 WO2019059953A2 (en) 2017-09-22 2017-09-26 DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE

Publications (1)

Publication Number Publication Date
MX2020002769A true MX2020002769A (es) 2020-07-20

Family

ID=65200304

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002769A MX2020002769A (es) 2017-09-22 2017-09-26 Composiciones de polvo seco con estearato de magnesio.
MX2023006856A MX2023006856A (es) 2017-09-22 2020-03-12 Composiciones de polvo seco con estearato de magnesio.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006856A MX2023006856A (es) 2017-09-22 2020-03-12 Composiciones de polvo seco con estearato de magnesio.

Country Status (9)

Country Link
US (3) US10195147B1 (cg-RX-API-DMAC7.html)
EP (1) EP3684338A4 (cg-RX-API-DMAC7.html)
JP (2) JP7493449B2 (cg-RX-API-DMAC7.html)
KR (2) KR102681843B1 (cg-RX-API-DMAC7.html)
CN (2) CN111315363B (cg-RX-API-DMAC7.html)
AU (1) AU2017432640B2 (cg-RX-API-DMAC7.html)
CA (1) CA3076353A1 (cg-RX-API-DMAC7.html)
MX (2) MX2020002769A (cg-RX-API-DMAC7.html)
WO (1) WO2019059953A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473133A (zh) * 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
EP3393517B1 (en) * 2015-12-22 2021-08-11 AspiAir GmbH Acetylsalicylic acid for use in the treatment of moderate to severe influenza
EP3463378A4 (en) * 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
EP3630120A4 (en) 2017-05-30 2021-01-13 Rhoshan Pharmaceuticals, Inc. DEPOSITION IN A VIAL OF A STABLE, STERILE AND CRYSTALLINE O-ACETYL-SALICYLIC ACID (ASPIRINE)
CA3076353A1 (en) * 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
NL2021637B1 (en) * 2018-09-14 2020-05-07 Stichting Katholieke Univ Breath sampler
EP4493276A4 (en) * 2022-03-18 2025-03-05 Pulmocures Ilac Egitim Danismanlik A.S. DOSAGE FORMS OF ACTIVE AGENTS AGAINST VIRAL DISEASES IN DRY POWDER INHALATOR DEVICES FOR SYMPTOMS DUE TO COVID-19 AND OTHER VIRAL LUNG DISEASES
US20250268829A1 (en) * 2022-04-22 2025-08-28 Board Of Regents, The University Of Texas System Inhaled antibacterial formulations for treating lung infections
JPWO2024246967A1 (cg-RX-API-DMAC7.html) * 2023-05-26 2024-12-05

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
JPS61140520A (ja) 1984-12-12 1986-06-27 Lion Corp アセチルサリチル酸製剤
FR2580634B1 (fr) 1985-04-19 1988-08-05 Rhone Poulenc Sante Nouveau derive de l'acide acetylsalicylique, sa preparation et les compositions pharmaceutiques qui le contiennent
DE3814856A1 (de) 1988-05-02 1989-11-16 Verla Pharm Mittel zur prophylaxe des herzinfarkts und zur verhuetung des reinfarkts
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US20070116761A1 (en) 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5533502A (en) 1993-05-28 1996-07-09 Vortran Medical Technology, Inc. Powder inhaler with aerosolization occurring within each individual powder receptacle
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
KR20010111564A (ko) 1998-11-12 2001-12-19 프랭크 쥐. 필키윅즈 흡입 시스템
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
US20030176421A1 (en) 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
PL204106B1 (pl) 2000-02-28 2009-12-31 Pharmakodex Ltd Zestaw do dostarczania środka terapeutycznego
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0010709D0 (en) 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
EP1177805A1 (en) 2000-07-31 2002-02-06 Maryland Financial Inc. Powder inhaler
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
NZ526059A (en) 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
WO2002051389A2 (en) 2000-12-22 2002-07-04 Aspen Aerogels, Inc. Aerogel powder comprising therapeutic agents
EP1238680B1 (en) 2001-03-05 2003-12-10 Ivo Pera Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract
US20060293217A1 (en) 2001-03-19 2006-12-28 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
US20040049022A1 (en) 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
GB0129270D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
GB0129397D0 (en) 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
AU2003276131A1 (en) 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
GB0226105D0 (en) 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
AU2004229567A1 (en) 2003-04-09 2004-10-28 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
AU2004229446B2 (en) 2003-04-09 2010-02-25 Bgp Products Operations Gmbh Aerosolization apparatus with air inlet shield
GB0312419D0 (en) 2003-05-30 2003-07-02 Boots Healthcare Int Ltd Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
US7041286B2 (en) 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
JP2007502815A (ja) 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Ppar調節因子
CN1838958A (zh) 2003-08-22 2006-09-27 贝林格尔·英格海姆药物公司 治疗慢性阻塞性肺病和肺动脉高血压的方法
US20050249697A1 (en) 2003-09-24 2005-11-10 Uhrich Kathryn E Compositions and methods for the inhibition of bone growth and resorption
JP5303605B2 (ja) * 2003-10-16 2013-10-02 第一三共ヘルスケア株式会社 サリチル酸類含有経口組成物
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
WO2005041886A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Methods for generating or increasing revenues related to pain inhibitor commerce
US20070232575A1 (en) 2004-02-05 2007-10-04 Baulieu Etienne E Treatment of Pulmonary Artery Hypertension with Dhea, Dheas, Dhea Analogs, or Dhea Derivatives
AU2005216969A1 (en) 2004-02-23 2005-09-09 Prolexys Pharmaceuticals Inc. Non-peptidyl agents with pHSP20-like activity, and uses thereof
AU2005238291A1 (en) 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
US7189750B2 (en) 2004-05-05 2007-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof
US7244709B2 (en) 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
WO2006017354A1 (en) 2004-07-13 2006-02-16 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing disease or pain
WO2006017505A2 (en) 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
ATE539757T1 (de) 2004-11-02 2012-01-15 Univ Leland Stanford Junior Verfahren zur hemmung von nkt-zellen
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
EP1898911A1 (en) * 2005-06-13 2008-03-19 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20090220435A1 (en) 2005-07-27 2009-09-03 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
JP2009504805A (ja) 2005-08-09 2009-02-05 ナノバイオ コーポレーション 抗炎症活性を有するナノエマルジョン組成物
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20070178166A1 (en) 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
MX2008007697A (es) 2005-12-16 2008-09-26 Univ Kansas Nanocumulos para la distribucion de farmacos.
WO2007072503A2 (en) 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
WO2007114881A1 (en) 2006-01-24 2007-10-11 Nexbio, Inc. Technology for preparation of macromolecular microspheres
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
PT2068889T (pt) 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
GB0617171D0 (en) 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
GB0621957D0 (en) 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
GB0700839D0 (en) 2007-01-17 2007-02-21 Braithwaite Philip Device
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2170958A1 (en) 2007-06-13 2010-04-07 Amgen Inc. Il-17 heteromeric receptor complex
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
RU2010102865A (ru) 2007-07-24 2011-08-27 НексБио, Инк. (US) Технология изготовления микрочастиц
WO2009019598A2 (en) * 2007-08-03 2009-02-12 Dr. Reddy's Laboratories Ltd. Inhalation therapy for respiratory disorders
WO2009026434A1 (en) 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
US9358242B2 (en) 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
EP2227085A4 (en) 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
US20090196930A1 (en) 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
DE102008004386A1 (de) 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
JP2011510017A (ja) 2008-01-15 2011-03-31 ユニベルシテ・ドウ・ストラスブール 治療薬として有用なレゾルシン酸ラクトンの合成
JP2011514335A (ja) 2008-02-21 2011-05-06 アムジェン インコーポレイテッド Il−17ra−il−17rbアンタゴニストおよび該アンタゴニストの使用
EP2255797A4 (en) 2008-02-22 2011-09-07 Hanall Biopharma Co Ltd COMPOSITE PREPARATION
GB0803369D0 (en) 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
MX2010010877A (es) 2008-04-04 2010-10-26 Irm Llc Compuestos y composiciones como inhibidores de itpkb.
CN102065694A (zh) 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
CA2722418C (en) 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
EP2318049A1 (en) 2008-07-15 2011-05-11 Schering Corporation Intranasal compositions comprising a decongestant and a corticosteroid
WO2010007447A1 (en) 2008-07-18 2010-01-21 Prosonix Limited Process for improving crystallinity
WO2010011329A2 (en) 2008-07-23 2010-01-28 Map Pharmaceuticals, Inc. The delivery of powdered drug via inhalation
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
MX2011002688A (es) 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
PE20120647A1 (es) 2009-03-13 2012-05-31 Nucitec Sa De Cv Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular
US20120046251A1 (en) 2009-04-06 2012-02-23 The Regents Of The University Of California Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
CA2759026C (en) 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2010135340A2 (en) 2009-05-18 2010-11-25 3M Innovative Properties Company Dry powder inhalers
ES2662769T3 (es) 2009-05-18 2018-04-09 Adamis Pharmaceuticals Corporation Contadores de dosis de inhalador de polvo seco
JP2012528844A (ja) 2009-06-01 2012-11-15 バイオコピア リミテッド 好中球によって引き起こされる疾患の治療におけるアンレキサノクスの使用
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
MX2012011629A (es) 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
WO2012041717A1 (en) * 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
WO2012078804A1 (en) 2010-12-07 2012-06-14 Respira Therapeutics, Inc. Dry powder inhaler
CN102058886A (zh) 2010-12-20 2011-05-18 云南白药集团无锡药业有限公司 医用粉雾剂及其应用
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
GB201102237D0 (en) 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
CN108014340A (zh) 2011-04-12 2018-05-11 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法
US20120306613A1 (en) 2011-06-02 2012-12-06 Nokia Siemens Networks Oy Sensor allocation
US20140239525A1 (en) 2011-06-17 2014-08-28 Board Of Regents, University Of Texas System Inhalable pharmaceutical compositions
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2753323A1 (en) 2011-09-06 2014-07-16 Verona Pharma PLC Treating cough and tussive attacks
ES2644922T3 (es) 2011-12-16 2017-12-01 Indosys Limited Cartucho de dosis unitaria de medicamento y dispositivo de suministro
HK1205156A1 (en) 2012-01-31 2015-12-11 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
AU2013240139B2 (en) 2012-03-26 2017-02-23 Arroyo Biosciences L.L.C. Novel sphingosine 1-phosphate receptor antagonists
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
CN111700878A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
SG11201407676VA (en) 2012-05-21 2015-03-30 Agency Science Tech & Res A dry powder formulation
EP2863892B1 (en) 2012-06-20 2017-11-08 University Of Waterloo Mucoadhesive nanoparticle delivery system
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
EP2903622A1 (en) 2012-10-03 2015-08-12 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists
US20150284381A1 (en) 2012-11-07 2015-10-08 Merck Sharp & Dohme Corp. Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN110464724A (zh) 2013-01-28 2019-11-19 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
GB201305813D0 (en) 2013-03-28 2013-05-15 Vectura Ltd Compositions and methods
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
EP2999337A4 (en) 2013-05-23 2017-03-15 Aztherapies, Inc Methods for delivering cromolyn
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
ES2712129T3 (es) 2013-12-23 2019-05-09 Xiaoguang Wen Comprimido de doble capa y método de preparación del mismo
EP3107548B8 (en) * 2014-02-20 2022-07-20 Otitopic Inc. Dry powder formulations for inhalation
CA3177696A1 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
AU2015223056B2 (en) 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
US10344037B2 (en) 2014-03-26 2019-07-09 Canget BioTek Pharma LLC Use of the FL-one hundred eighteen core chemical structure platform to generate FL-one hundred eighteen derivatives for treatment of human disease
WO2015153838A1 (en) 2014-04-02 2015-10-08 Rogne Bioscience Inc. Methods and compositions for treating inflammatory disorders
EP3129013A1 (en) 2014-04-10 2017-02-15 Crowley, Patrick Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders
KR20150127315A (ko) 2014-05-07 2015-11-17 삼성중공업 주식회사 밸러스트수 처리 장치
CA2991760C (en) * 2014-07-31 2025-05-06 Aspeya US Inc. DRY INHALATION POWDER FORMULATIONS
US20180056022A1 (en) 2015-03-21 2018-03-01 James Zhou Liu Hand-actuated dry powder inhaler and its use
WO2016176552A1 (en) * 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
EP3463378A4 (en) * 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
CN106619549B (zh) * 2017-01-03 2019-12-06 江苏吴中医药集团有限公司苏州制药厂 一种替格瑞洛与阿司匹林复合片剂及其制备方法
CA3076353A1 (en) * 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) * 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
JP7690081B1 (ja) 2024-03-14 2025-06-09 ミサワホーム株式会社 モバイルユニットの連結構造

Also Published As

Publication number Publication date
US12508227B2 (en) 2025-12-30
KR102681843B1 (ko) 2024-07-05
KR102507987B1 (ko) 2023-03-21
EP3684338A4 (en) 2021-06-23
AU2017432640B2 (en) 2023-11-30
JP2021502954A (ja) 2021-02-04
EP3684338A2 (en) 2020-07-29
JP2022137070A (ja) 2022-09-21
JP7493449B2 (ja) 2024-05-31
AU2017432640A1 (en) 2020-03-19
US20190336448A1 (en) 2019-11-07
KR20230040375A (ko) 2023-03-22
MX2023006856A (es) 2023-06-22
CN111315363A (zh) 2020-06-19
US10195147B1 (en) 2019-02-05
WO2019059953A2 (en) 2019-03-28
WO2019059953A3 (en) 2019-09-26
US20220016030A1 (en) 2022-01-20
KR20200090755A (ko) 2020-07-29
CN115919780A (zh) 2023-04-07
CA3076353A1 (en) 2019-03-28
JP7561162B2 (ja) 2024-10-03
US11077058B2 (en) 2021-08-03
CN111315363B (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
MX2023006856A (es) Composiciones de polvo seco con estearato de magnesio.
ZA202006025B (en) Cryoprotective agents for particulate formulations
ZA202303338B (en) Orodispersible dosage unit containing an estetrol component
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
NZ723838A (en) Cannabinoid compositions and uses
EA202190331A1 (ru) Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
UY36703A (es) Composiciones y métodos para la administración de un polinucleótido en una planta
MX385820B (es) Unidad de dosificacion orodispersable que contiene un componente estetrol.
BR112019003015A2 (pt) composições hemostáticas e métodos de preparo das mesmas
EP4501404A3 (en) Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
MX375427B (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion
BR112015029773A2 (pt) pós revestidos com aroma
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
HK1220445A1 (zh) 具有摇溶性以及增强的溶解再现性和稳定性的组合物
WO2016038521A8 (en) Pharmaceutical compositions of liraglutide
MX387019B (es) Formulacion farmaceutica parenteral que contiene acido carglumico.
MY200499A (en) Sulfonamide pharmaceutical composition
BR112017003888A2 (pt) método de fabricação de uma formulação de pó seco, formulação, inalador de pó seco, uso de partículas comoídas por jatos e cocondicionadas, e, kit farmacêutico.
IN2013MU01177A (cg-RX-API-DMAC7.html)
WO2016109400A3 (en) Lipid-encapsulated gas microsphere compositions and related methods
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
AR116728A1 (es) Combinaciones de principios activos
WO2019151965A3 (en) Solid oral pharmaceutical compositions comprising apixaban